The Guggenheim Museum Bilbao launches its new in situ series with Living Architecture: Gehry, a digital installation by Refik Anadol. Using a custom AI model trained on Frank Gehry’s sketches ...

With the CSF-1R inhibitor space heating up, Merck KGaA has gone all-in on pimicotinib, paying Abbisko Therapeutics $85 million to secure the global license to the drug. The German pharma ...

with the German firm’s Merck Serono division licensing various technologies used to engineer T-cells to target cancers, including its RheoSwitch platform for controlling gene expression and ...

Merck, Bristol-Myers Squibb, and Johnson & Johnson were among the top performers in the S&P 500, with the sector also benefiting from its status as a defensive play. As the U.S. stock market ...

STANFORD, Calif. — Andrew Luck picked a familiar face to take over as Stanford’s interim football coach, hiring former NFL coach Frank Reich on Monday to replace the fired Troy Taylor.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

German chemical and pharma group Merck KGaA has acknowledged that it is in talks to buy US biotech SpringWorks, but cautioned there is no guarantee a deal will be forthcoming. Merck said in a ...

In October, Merck took up an option on the personalised RNA-based cancer vaccine with an upfront payment of $250 million as part of a collaboration first agreed in 2016 and expanded in 2018.

Five years removed from a Super Bowl title as the Philadelphia Eagles offensive coordinator, former Indianapolis Colts and Carolina Panthers head coach Frank Reich is going back to school ...

Merck & Co has entered into a worldwide licensing deal with Opko Health’s ModeX Therapeutics unit for a vaccine candidate against Epstein-Barr virus (EBV) that could be worth up to $922.5 ...